Melqart Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Melqart Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-150,000	Closed	-$32.9M	–	93
2021 Q4	$32.9M	Buy	150,000 +10,000	+7%	+$1.94M	1.67%	15
2021 Q3	$25.4M	Sell	140,000 -138,130	-50%	-$27M	1.22%	24
2021 Q2	$56.1M	Buy	278,130 +8,730	+3%	+$1.83M	2.52%	13
2021 Q1	$57.9M	Buy	269,400 +128,100	+91%	+$28.1M	2.62%	11
2020 Q4	$33.4M	Buy	141,300 +47,800	+51%	+$11M	2.52%	14
2020 Q3	$25.4M	Buy	93,500 +15,500	+20%	+$4.28M	2.83%	8
2020 Q2	$22.6M	Sell	78,000 -2,000	-3%	-$542K	2.8%	12
2020 Q1	$19M	Sell	80,000 -207,900	-72%	-$47.7M	1.88%	17
2019 Q4	$63M	Buy	287,900 +127,900	+80%	+$25.9M	5.28%	7
2019 Q3	$27.1M	Buy	160,000 +16,000	+11%	+$2.83M	2.46%	16
2019 Q2	$26.4M	Buy	144,000 +11,500	+9%	+$2.01M	1.82%	23
2019 Q1	$24.4M	Sell	132,500 -22,500	-15%	-$4.16M	2.26%	18
2018 Q4	$25.7M	Buy	+155,000	New	+$26.9M	3%	15
2018 Q3	–	Sell	-184,800	Closed	-$31.4M	–	28
2018 Q2	$31.4M	Buy	+184,800	New	+$28.6M	2.68%	13

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Melqart Asset Management's VRTX Position: Q1 2022 in Review

Melqart Asset Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2022, closing a stake of 150,000 shares — an estimated $32.9M sold.

Melqart Asset Management first reported a position in VRTX in Q2 2018 and held it in 14 quarters. The position peaked at $63M in Q4 2019. 1,071 funds tracked by Wall St. Rank hold VRTX as of Q1 2022.

Melqart Asset Management reported no remaining Vertex Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Melqart Asset Management sold 150,000 Vertex Pharmaceuticals shares in Q1 2022, an estimated $32.9M.
Melqart Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2018 and held it in 14 quarters.
Melqart Asset Management's Vertex Pharmaceuticals position peaked at $63M in Q4 2019.
1,071 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2022.

Based on Melqart Asset Management's 13F filing for Q1 2022, filed 16 May 2022.